98%
921
2 minutes
20
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1021/acs.jproteome.5c00609 | DOI Listing |
Pain Rep
October 2025
Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Introduction: Moderate-to-severe acute postsurgical pain (APSP) is experienced by approximately 30% of surgical patients.
Objectives: To improve early APSP management, we developed 2 pragmatic and generalizable point-of-care risk tools to preoperatively predict moderate-to-severe and severe APSP in the postanaesthesia care unit (PACU).
Methods: This was a multicenter prospective cohort study of adult patients undergoing elective surgical procedures between May 2021 and May 2023.
Front Immunol
September 2025
Medicine 1 Unit, Ca' Foncello University Hospital, Treviso, Italy.
Background: Anti-integrin αvβ6 IgG autoantibodies showed good sensitivity and optimal specificity in ulcerative colitis (UC) compared to controls. We aim at confirming the diagnostic accuracy of anti-integrin αvβ6 autoantibodies in an Italian multicentric cohort.
Methods: This observational multicentric study included adult and pediatric patients with inflammatory bowel disease and controls.
Ann Surg Oncol
September 2025
Department of HPB Surgery and Liver Transplant, Royal Free Hospital NHS Foundation Trust, London, UK.
Spine Deform
September 2025
Department of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA.
Purpose: A subset of adult spinal deformity (ASD) patients undergoing corrective surgery receive a disproportionate level of medical resources and incur greater costs. We examined the characteristics of such super-utilizers of health care resources among ASD patients.
Methods: This prospective, multicenter study analyzed data from ASD patients with > 4 levels of spinal fusion and a minimum 2-year follow-up.
J Endocrinol Invest
September 2025
Department of Endocrinology and Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden.
Purpose: Patients with primary adrenal insufficiency (PAI) require mineralocorticoid replacement therapy in addition to glucocorticoids. These therapies should be considered in combination because most glucocorticoids also possess mineralocorticoid activity. We aimed to investigate the relationship between fludrocortisone and hydrocortisone-equivalent dosing in patients with PAI.
View Article and Find Full Text PDF